| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Gross Sales | 4,118.16 | 4,178.18 | 3,654.82 | 3,671.89 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 4,118.16 | 4,178.18 | 3,654.82 | 3,671.89 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 68.82 | 34.03 | 46.11 | 22.83 |
Total Income | 4,186.98 | 4,212.21 | 3,700.93 | 3,694.73 |
Total Expenditure | 3,653.68 | 4,081.23 | 3,391.57 | 3,776.59 |
PBIDT | 533.3 | 130.98 | 309.35 | -81.86 |
Interest | 34.6 | 50.61 | 46.25 | 16.66 |
PBDT | 498.7 | 80.36 | 263.11 | -98.52 |
Depreciation | 153.45 | 125.64 | 112.81 | 94.68 |
Minority Interest Before NP | 0 | 0 | 0 | 0 |
Tax | 80.91 | 75.54 | 79.74 | 63.72 |
Deferred Tax | -79.43 | -121.61 | -27.26 | -6.04 |
Reported Profit After Tax | 343.78 | 0.79 | 97.82 | -250.87 |
Minority Interest After NP | 5.6 | 4.83 | 0 | 0 |
Net Profit after Minority Interest | 338.18 | -4.04 | 97.82 | -250.87 |
Extra-ordinary Items | 12.78 | 17.4 | -34.97 | -8.7 |
Adjusted Profit After Extra-ordinary item | 325.4 | -21.44 | 132.79 | -242.17 |
EPS (Unit Curr.) | 22.6 | -0.28 | 6.63 | -17.65 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 |
Equity | 30.62 | 28.61 | 28.61 | 28.61 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 |
PBIDTM(%) | 12.94 | 3.13 | 8.46 | -2.22 |
PBDTM(%) | 12.1 | 1.92 | 7.19 | -2.68 |
PATM(%) | 8.34 | 0.01 | 2.67 | -6.83 |
The organisation is the largest CDMO serving the Indian pharmaceutical industry, with a proven track record and a broad clientele.
The IPO comprised a fresh issue of shares worth ₹680 crore and an offer-for-sale (OFS) of 1.73 crore shares, aggregating ₹1,177 crore.
The IPO consists of a fresh issue of ₹680 crore and an offer for sale (OFS) of up to 1.73 crore shares at a face value of ₹2 each.
On Monday, the business said that it had received ₹829 crore from anchor investors ahead of the public share sale subscription period.
The IPO includes a new issue of 1 Crore shares worth ₹680.00 Crore and an offer for sale of 1.73 Crore shares worth ₹1,176.74 Crore.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
